In the only open-label trial of secukinumab at 2 dosage levels (every 2 weeks or every 4 weeks, administration of 300 mg secukinumab after the loading dose of 5 weekly injections), HiSCR, after 24 weeks, was achieved by 70% of all 20 HS patients (including 6 patients with previous anti-TNF-α exposure). Here, TNF is linked to histiocytic sarcoma.